New

Taiho Pharmaceutical

The AI engine Fit Assessment

Beta

The company operates in pharmaceutics and pharmaceutical development, demonstrated by a patent for a dry coated tablet containing tegafur, gimeracil, and potassium oteracil, indicating a pharma tech focus. Check Source

Blurb

Taiho Pharmaceutical is a pharmaceutical company that develops and markets treatments in the field of oncology.

HQ Location

Tokyo (Japan)

Founded

1963

Employees

1001 - 5000

Total funding raised

Not available

Funding Status

Not available

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.